08 May 2021: Review Articles
A Review of Recent Research on the Role of MicroRNAs in Renal Cancer
Longfei Yang 1ABCDE , Xiaofeng Zou 2G , Junrong Zou 3D , Guoxi Zhang 2FG*DOI: 10.12659/MSM.930639
Med Sci Monit 2021; 27:e930639
Table 2 miRNAs act as oncogenes in renal cancer. A summary of miRNAs name, specimen types, targeted messenger RNAs, functions and clinical applicant is provided.
| MicroRNA | Specimen | biological Function | clinical application | Target | Pathways | Refs. |
|---|---|---|---|---|---|---|
| miR-154-5p | In vitro | Promote cell proliferation, migration, invasion and inhibit apoptosis | OS | []2 | ||
| miR-92b-3p | In vitro | Promote cell proliferation, migration and invasion, decrease expression of TSC1 and enhance p-p70S6 kinase | OS | TSC1 | mTOR signaling pathway | []65 |
| miR-501-5p | In vitro and in vivo | Increase cell autophagy, growth, migration and activate mTOR kinase | mTOR signaling pathway | []66 | ||
| miR-25-3p | In vitro | Enhance cell migration and increase expression of N-cadherin and Slug | OS | IMPA2 | []68 | |
| miR-146a-5p | In vitro | Increase cell proliferation and improve expression of G6PD and TKT | Metabolic related mechanism | []69 | ||
| miR-193a-3p and -224 | In vitro | Promote cell proliferation, invasion, migration and inhibit apoptosis, improve expression of PI3k and p-Akt | ST3GalIV | PI3K/Akt signaling pathway | []71 | |
| miR-19 | In vitro | Enhance cell proliferation and inhibit expression of FRK and PTEN | FRK and PTEN | PI3K/Akt signaling pathway | []72 | |
| miR-122 | In vitro and in vivo | Promote tumor growth, enhance expression of ZEB1 and ZEB2, p-Erk1/2 and p38 | PFS | FOXO3 and occludin | PI3K/Akt, MAPK signaling pathway | [, ]73 |
| miR-142-5p | In vitro | Increase cell proliferation and migration | BTG3 | []75 | ||
| miR-452-5p | In vitro and in vivo | Enhance tumor metastasis | OS, target | SMAD4 | TGF-β signaling pathway | []77 |
| miR-1274a | In vitro | Promote cell proliferation and inhibit apoptosis | BMPR1B | []79 | ||
| miR-543 | In vitro and in vivo | Facilitate tumor growth, metastasis and increase expression β-catenin and p-GSK-3β, while inhibit expression of p21 | DKK1, KLF6 | Wnt signaling pathway | [, ]82 | |
| miR-125b | In vitro and in vivo | Promote tumor growth and metastasis, inhibit sensitivity of cells to doxorubicin and sunitinib | DKK3 | Wnt signaling pathway | []83 | |
| miR-146b-5p | In vitro and in vivo | Inhibit expression of p65 and TRAF6 | TRAF6 | NF-κB signaling pathway | []84 | |
| miR-381-3p | In vitro | Inhibit TNF-induced cell apoptosis and necroptosis | OS | RIPK3 | []89 | |
| miR-223-3p | In vitro | Promote cell proliferation, migration, invasion and increase expression of KRAS | OS | SLC4A4 | RAS signaling pathway | []90 |
| miR-21 | In vitro and in serum | Increase cell proliferation, invasion, migration and reduce apoptosis, decrease expression of p53 and p21, Bax, cyclin E2, VEGFA and p-c-Jun | Diagnosis, target | PTEN, PDCD4 | PI3K/AKT and NF-κB signaling pathway | [,,]8 |
| miR-204-5p | In urine/mice/RCC tissues | Liquid biopsy | []96 | |||
| miR-301a-3p and -1293 | In plasma | Liquid biopsy | []97 | |||
| miR-19b-3p | In vitro and in exosomes | Enhance cell migration and invasion, while impair expression of E-cadherin and PTEN | Diagnosis | []99 | ||
| miR-130b/18a/ 223 | In RCC tissues | Diagnosis | []108 | |||
| miR-15a/ 182/138/200c/16/ 210/34a/155 | In RCC tissues | Diagnosis | []104 | |||
| miR-3199-2/ 1293 | In RCC tissues | Diagnosis | []105 | |||
| miR-21/142/150/ 155 | In RCC tissues | Diagnosis | []106 | |||
| miR-489-3p/630 | In vitro | Promote cell proliferation and chemoresistance to oxaliplatin | OCT2 | []110 | ||
| miR-720 | In vitro and in vivo | Promote tumor growth | OS, diagnosis | E-cadherin and αE-catenin | []118 | |
| miR-23a-3p | In vitro | Promote cell proliferation, migration and invasion, while inhibit apoptosis | OS | PNRC2 | []117 | |
| miR-572 | In vitro | Promote cell proliferation, migration, invasion and inhibit cell apoptosis | OS | []4 | ||
| miR-221-5p | In vitro | Promote cell proliferation, migration, invasion and inhibit apoptosis | OS | []114 | ||
| miR-566 | In vitro | Promote cell proliferation, migration, invasion and inhibit apoptosis | OS | []115 | ||
| miR-663a | In vitro | Promote cell proliferation, invasion, migration and inhibit apoptosis | OS | []116 | ||
| miR-155-5p/ 210-3p | In RCC tissues | Biomarker of recurrence | []123 | |||
| OS – overall survival; TSC1 – tuberous sclerosis complex subunit 1; mTOR – mammalian target of rapamycin; IMPA2 – myo-inositol monophosphatase 2; G6PD – glucose-6-phosphate dehydrogenase; TKT – transketolase; ST3GalIV – alpha-2,3-sialyltransferase IV; PI3K – phosphatidylinositol 3-kinase; AKT – protein kinase B; FRK – fyn-related kinase; PTEN – phosphatase and tensin homolog deleted on chromosome 10; ZEB1 – zinc finger E-box binding homeobox 1; Erk – extracellular signal regulated kinase; PFS – progression-free survival; FOXO3 – forkhead box O3; BTG3 – B-cell translocation gene 3; TGF-β – transforming growth factor-β; SMAD4 – SMAD family member 4; BMPR1B – bone morphogenetic protein receptor type 1B; DKK1/3 – Dickkopf1/3; KLF6 – Kruppel-like factor 6; TRAF6 – TNF receptor associated factor 6; RIPK3 – receptor-interacting protein kinase 1; SLC4A4 – solute carrier family 4; PDCD4 – programmed cell death 4; VEGFA – vascular endothelial growth factor A; OCT2 – octamer binding transcription factor 2; pnrc2 – proline-rich nuclear receptor co-activator 2. | ||||||